Publication: Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis
dc.contributor.author | Richard J. Allen | en_US |
dc.contributor.author | Beatriz Guillen-Guio | en_US |
dc.contributor.author | Justin M. Oldham | en_US |
dc.contributor.author | Shwu Fan Ma | en_US |
dc.contributor.author | Amy Dressen | en_US |
dc.contributor.author | Megan L. Paynton | en_US |
dc.contributor.author | Luke M. Kraven | en_US |
dc.contributor.author | Ma'en Obeidat | en_US |
dc.contributor.author | Xuan Li | en_US |
dc.contributor.author | Michael Ng | en_US |
dc.contributor.author | Rebecca Braybrooke | en_US |
dc.contributor.author | Maria Molina-Molina | en_US |
dc.contributor.author | Brian D. Hobbs | en_US |
dc.contributor.author | Rachel K. Putman | en_US |
dc.contributor.author | Phuwanat Sakornsakolpat | en_US |
dc.contributor.author | Helen L. Booth | en_US |
dc.contributor.author | William A. Fahy | en_US |
dc.contributor.author | Simon P. Hart | en_US |
dc.contributor.author | Mike R. Hill | en_US |
dc.contributor.author | Nik Hirani | en_US |
dc.contributor.author | Richard B. Hubbard | en_US |
dc.contributor.author | Robin J. McAnulty | en_US |
dc.contributor.author | Ann B. Millar | en_US |
dc.contributor.author | Vidyia Navaratnam | en_US |
dc.contributor.author | Eunice Oballa | en_US |
dc.contributor.author | Helen Parfrey | en_US |
dc.contributor.author | Gauri Saini | en_US |
dc.contributor.author | Moira K.B. Whyte | en_US |
dc.contributor.author | Yingze Zhang | en_US |
dc.contributor.author | Naftali Kaminski | en_US |
dc.contributor.author | Ayodeji Adegunsoye | en_US |
dc.contributor.author | Mary E. Strek | en_US |
dc.contributor.author | Margaret Neighbors | en_US |
dc.contributor.author | Xuting R. Sheng | en_US |
dc.contributor.author | Gunnar Gudmundsson | en_US |
dc.contributor.author | Vilmundur Gudnason | en_US |
dc.contributor.author | Hiroto Hatabu | en_US |
dc.contributor.author | David J. Lederer | en_US |
dc.contributor.author | Ani Manichaikul | en_US |
dc.contributor.author | John D. Newell | en_US |
dc.contributor.author | George T. O'Connor | en_US |
dc.contributor.author | Victor E. Ortega | en_US |
dc.contributor.author | Hanfei Xu | en_US |
dc.contributor.author | Tasha E. Fingerlin | en_US |
dc.contributor.author | Yohan Bossé | en_US |
dc.contributor.author | Ke Hao | en_US |
dc.contributor.author | Philippe Joubert | en_US |
dc.contributor.author | David C. Nickle | en_US |
dc.contributor.author | Don D. Sin | en_US |
dc.contributor.author | Wim Timens | en_US |
dc.contributor.author | Dominic Furniss | en_US |
dc.contributor.author | Andrew P. Morris | en_US |
dc.contributor.author | Krina T. Zondervan | en_US |
dc.contributor.author | Ian P. Hall | en_US |
dc.contributor.author | Ian Sayers | en_US |
dc.contributor.author | Martin D. Tobin | en_US |
dc.contributor.author | M. Toby | en_US |
dc.contributor.author | Michael H. Cho | en_US |
dc.contributor.author | Gary M. Hunninghake | en_US |
dc.contributor.author | David A. Schwartz | en_US |
dc.contributor.author | Brian L. Yaspan | en_US |
dc.contributor.author | Philip L. Molyneaux | en_US |
dc.contributor.author | Carlos Flores | en_US |
dc.contributor.author | Imre Noth | en_US |
dc.contributor.author | R. Gisli Jenkins | en_US |
dc.contributor.author | Louise V. Wain | en_US |
dc.contributor.other | Centro de Investigación Biomédica en Red de Enfermedades Respiratorias | en_US |
dc.contributor.other | National Jewish Health | en_US |
dc.contributor.other | Wellcome Trust Centre for Human Genetics | en_US |
dc.contributor.other | Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval | en_US |
dc.contributor.other | Instituto Tecnológico y de Energías Renovables, S.A. | en_US |
dc.contributor.other | Landspitali University Hospital | en_US |
dc.contributor.other | Icelandic Heart Association | en_US |
dc.contributor.other | Haskoli Islands | en_US |
dc.contributor.other | Papworth Hospital, NHS Foundation Trust | en_US |
dc.contributor.other | University of Leicester | en_US |
dc.contributor.other | Wake Forest School of Medicine | en_US |
dc.contributor.other | The University of Chicago | en_US |
dc.contributor.other | Columbia University Irving Medical Center | en_US |
dc.contributor.other | University of Edinburgh | en_US |
dc.contributor.other | University of Oxford | en_US |
dc.contributor.other | Genentech Incorporated | en_US |
dc.contributor.other | Institut d'Investigació Biomedica de Bellvitge | en_US |
dc.contributor.other | Castle Hill Hospital | en_US |
dc.contributor.other | Nottingham University Hospitals NHS Trust | en_US |
dc.contributor.other | Framingham Heart Study | en_US |
dc.contributor.other | UCL | en_US |
dc.contributor.other | University of Virginia | en_US |
dc.contributor.other | University of Liverpool | en_US |
dc.contributor.other | University of Bristol | en_US |
dc.contributor.other | GlaxoSmithKline plc. | en_US |
dc.contributor.other | Boston University | en_US |
dc.contributor.other | Yale School of Medicine | en_US |
dc.contributor.other | Brigham and Women's Hospital | en_US |
dc.contributor.other | University of Pittsburgh | en_US |
dc.contributor.other | University of Washington, Seattle | en_US |
dc.contributor.other | University of Nottingham | en_US |
dc.contributor.other | University of California, Davis | en_US |
dc.contributor.other | Icahn School of Medicine at Mount Sinai | en_US |
dc.contributor.other | Vagelos College of Physicians and Surgeons | en_US |
dc.contributor.other | Faculty of Medicine, Siriraj Hospital, Mahidol University | en_US |
dc.contributor.other | National Heart and Lung Institute | en_US |
dc.contributor.other | The University of British Columbia | en_US |
dc.contributor.other | University of Colorado at Denver | en_US |
dc.contributor.other | University of Iowa Carver College of Medicine | en_US |
dc.contributor.other | Glenfield Hospital | en_US |
dc.contributor.other | Royal Brompton Hospital | en_US |
dc.contributor.other | Merck & Co., Inc. | en_US |
dc.contributor.other | University of Groningen, University Medical Center Groningen | en_US |
dc.contributor.other | University of Manchester | en_US |
dc.contributor.other | Universidad de la Laguna | en_US |
dc.contributor.other | Universitat de Barcelona | en_US |
dc.contributor.other | Groningen Research Institute for Asthma and COPD | en_US |
dc.contributor.other | Hospital Ntra | en_US |
dc.date.accessioned | 2020-03-26T04:54:52Z | |
dc.date.available | 2020-03-26T04:54:52Z | |
dc.date.issued | 2020-03-01 | en_US |
dc.description.abstract | © 2020 by the American Thoracic Society. Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease characterized by scarring of the lung that is believed to result from an atypical response to injury of the epithelium. Genome-wide association studies have reported signals of association implicating multiple pathways including host defense, telomere maintenance, signaling, and cell-cell adhesion. Objectives: To improve our understanding of factors that increase IPF susceptibility by identifying previously unreported genetic associations. Methods: We conducted genome-wide analyses across three independent studies and meta-analyzed these results to generate the largest genome-wide association study of IPF to date (2,668 IPF cases and 8,591 controls). We performed replication in two independent studies (1,456 IPF cases and 11,874 controls) and functional analyses (including statistical fine-mapping, investigations into gene expression, and testing for enrichment of IPF susceptibility signals in regulatory regions) to determine putatively causal genes. Polygenic risk scores were used to assess the collective effect of variants not reported as associated with IPF. Measurements and Main Results: We identified and replicated threenewgenome-wide significant (P<5×10-8) signals of association with IPF susceptibility (associated with altered gene expression of KIF15, MAD1L1, and DEPTOR) and confirmed associations at 11 previously reported loci. Polygenic risk score analyses showed that the combined effect of many thousands of as yet unreported IPF susceptibility variants contribute to IPF susceptibility. Conclusions: The observation that decreased DEPTOR expression associates with increased susceptibility to IPF supports recent studies demonstrating the importance of mTOR signaling in lung fibrosis. New signals of association implicating KIF15 and MAD1L1 suggest a possible role of mitotic spindle-assembly genes in IPF susceptibility. | en_US |
dc.identifier.citation | American Journal of Respiratory and Critical Care Medicine. Vol.201, No.5 (2020), 564-574 | en_US |
dc.identifier.doi | 10.1164/rccm.201905-1017OC | en_US |
dc.identifier.issn | 15354970 | en_US |
dc.identifier.issn | 1073449X | en_US |
dc.identifier.other | 2-s2.0-85080088253 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/53750 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85080088253&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85080088253&origin=inward | en_US |